Melur Ramakrishnaiah
Examiner (ID: 70, Phone: (571)272-8098 , Office: P/2656 )
Most Active Art Unit | 2656 |
Art Unit(s) | 2614, 2691, 2743, 2643, 2656, 2651 |
Total Applications | 3169 |
Issued Applications | 2675 |
Pending Applications | 81 |
Abandoned Applications | 413 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18817507
[patent_doc_number] => 20230391847
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => PROCESSES FOR MAKING AND USING A CELLULAR FIBRONECTIN COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 18/448294
[patent_app_country] => US
[patent_app_date] => 2023-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26674
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448294
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/448294 | Methods for treating an ocular condition with cellular fibronectin compositions | Aug 10, 2023 | Issued |
Array
(
[id] => 18808653
[patent_doc_number] => 20230382987
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USESTHEREOF FOR TREATING CANCER CACHEXIA AND CANCER
[patent_app_type] => utility
[patent_app_number] => 18/364173
[patent_app_country] => US
[patent_app_date] => 2023-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25782
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -55
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18364173
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/364173 | MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USESTHEREOF FOR TREATING CANCER CACHEXIA AND CANCER | Aug 1, 2023 | Pending |
Array
(
[id] => 18754013
[patent_doc_number] => 20230357377
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONIST
[patent_app_type] => utility
[patent_app_number] => 18/339147
[patent_app_country] => US
[patent_app_date] => 2023-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9400
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18339147
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/339147 | Methods of altering bone growth by administration of Sost or Wise antagonist or agonist | Jun 20, 2023 | Issued |
Array
(
[id] => 18922982
[patent_doc_number] => 20240025986
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => THERAPY FOR GLAUCOMA AND OPTIC NEUROPATHY BY TARGETING COLONY STIMULATING FACTORS
[patent_app_type] => utility
[patent_app_number] => 18/318336
[patent_app_country] => US
[patent_app_date] => 2023-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14606
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18318336
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/318336 | THERAPY FOR GLAUCOMA AND OPTIC NEUROPATHY BY TARGETING COLONY STIMULATING FACTORS | May 15, 2023 | Pending |
Array
(
[id] => 18598422
[patent_doc_number] => 20230273221
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => METHOD RELATING TO MYOSTATIN PATHWAY INHIBITION
[patent_app_type] => utility
[patent_app_number] => 18/312879
[patent_app_country] => US
[patent_app_date] => 2023-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10163
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312879
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/312879 | METHOD RELATING TO MYOSTATIN PATHWAY INHIBITION | May 4, 2023 | Pending |
Array
(
[id] => 18970452
[patent_doc_number] => 20240050544
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => COMBINATION THERAPY WITH SEMAPHORIN-4D BLOCKADE (SEMA4D) AND DC1 THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/307920
[patent_app_country] => US
[patent_app_date] => 2023-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18020
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18307920
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/307920 | COMBINATION THERAPY WITH SEMAPHORIN-4D BLOCKADE (SEMA4D) AND DC1 THERAPY | Apr 26, 2023 | Pending |
Array
(
[id] => 18770867
[patent_doc_number] => 20230365669
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA
[patent_app_type] => utility
[patent_app_number] => 18/297280
[patent_app_country] => US
[patent_app_date] => 2023-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16254
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18297280
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/297280 | USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA | Apr 6, 2023 | Pending |
Array
(
[id] => 18748385
[patent_doc_number] => 11807681
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-07
[patent_title] => Methods of altering bone growth by administration of Sost or Wise antagonist or agonist
[patent_app_type] => utility
[patent_app_number] => 18/123569
[patent_app_country] => US
[patent_app_date] => 2023-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9424
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18123569
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/123569 | Methods of altering bone growth by administration of Sost or Wise antagonist or agonist | Mar 19, 2023 | Issued |
Array
(
[id] => 18581610
[patent_doc_number] => 20230263862
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => FORMATION OF BONE
[patent_app_type] => utility
[patent_app_number] => 18/183676
[patent_app_country] => US
[patent_app_date] => 2023-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10140
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18183676
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/183676 | FORMATION OF BONE | Mar 13, 2023 | Pending |
Array
(
[id] => 18860243
[patent_doc_number] => 20230414677
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/175409
[patent_app_country] => US
[patent_app_date] => 2023-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63726
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18175409
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/175409 | ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION | Feb 26, 2023 | Pending |
Array
(
[id] => 18647858
[patent_doc_number] => 20230293634
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING BONE AND OTHER DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/156015
[patent_app_country] => US
[patent_app_date] => 2023-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37282
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156015
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/156015 | ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING BONE AND OTHER DISORDERS | Jan 17, 2023 | Pending |
Array
(
[id] => 18955158
[patent_doc_number] => 20240043485
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => THERAPEUTIC USE OF BONE MORPHOGENETIC PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/149403
[patent_app_country] => US
[patent_app_date] => 2023-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9139
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18149403
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/149403 | THERAPEUTIC USE OF BONE MORPHOGENETIC PROTEINS | Jan 2, 2023 | |
Array
(
[id] => 18675113
[patent_doc_number] => 20230312696
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => Compositions and Methods of Use for Treating Metabolic Disorders
[patent_app_type] => utility
[patent_app_number] => 17/982390
[patent_app_country] => US
[patent_app_date] => 2022-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29714
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17982390
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/982390 | Compositions and Methods of Use for Treating Metabolic Disorders | Nov 6, 2022 | Pending |
Array
(
[id] => 18657734
[patent_doc_number] => 20230303686
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/971520
[patent_app_country] => US
[patent_app_date] => 2022-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46729
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17971520
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/971520 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES | Oct 20, 2022 | Pending |
Array
(
[id] => 18522995
[patent_doc_number] => 20230233648
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION
[patent_app_type] => utility
[patent_app_number] => 17/960911
[patent_app_country] => US
[patent_app_date] => 2022-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68689
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17960911
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/960911 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION | Oct 5, 2022 | Pending |
Array
(
[id] => 18649475
[patent_doc_number] => 20230295288
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => ANTIBODY VARIANTS
[patent_app_type] => utility
[patent_app_number] => 17/948814
[patent_app_country] => US
[patent_app_date] => 2022-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14325
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17948814
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/948814 | ANTIBODY VARIANTS | Sep 19, 2022 | Pending |
Array
(
[id] => 18649472
[patent_doc_number] => 20230295285
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT
[patent_app_type] => utility
[patent_app_number] => 17/939634
[patent_app_country] => US
[patent_app_date] => 2022-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10078
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17939634
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/939634 | METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT | Sep 6, 2022 | Pending |
Array
(
[id] => 18553259
[patent_doc_number] => 20230251271
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => METABOLIC BIOMARKERS FOR PREDICTING RESPONSIVENESS TO FGF-18 COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/930389
[patent_app_country] => US
[patent_app_date] => 2022-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11223
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930389
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930389 | METABOLIC BIOMARKERS FOR PREDICTING RESPONSIVENESS TO FGF-18 COMPOUND | Sep 6, 2022 | Pending |
Array
(
[id] => 18568323
[patent_doc_number] => 20230258659
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => INFLAMMATORY BIOMARKERS FOR PREDICTING RESPONSIVENESS TO FGF-18 COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/929261
[patent_app_country] => US
[patent_app_date] => 2022-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12068
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929261
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/929261 | INFLAMMATORY BIOMARKERS FOR PREDICTING RESPONSIVENESS TO FGF-18 COMPOUND | Aug 31, 2022 | Pending |
Array
(
[id] => 18036233
[patent_doc_number] => 20220380448
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/816484
[patent_app_country] => US
[patent_app_date] => 2022-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54943
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816484
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/816484 | ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | Jul 31, 2022 | Pending |